FrancophonIA/ELRC3.0 huggingface dataset:
English: Clopidogrel HEXAL is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Maltese: Clopidogrel HEXAL jittieħed biex inaqqas ir-riskju li emboli tad-demm (trombi) jifformaw fl-arterji mwebbsin (arterji), proċess imsejjaħ aterotrombosi, li jista' jwassal għal konsegwenzi aterotrombotiċi (bħal puplesija, attakk tal-qalb, jew mewt).
English: Clopidogrel
Maltese: OĦRAJN
English: • You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE EFFECTS').
Maltese: Għandek ukoll tgħid lit-tabib tiegħek minnufih jekk tiżviluppa kundizzjoni medika (magħrufa wkoll bħala Purpura Trombotika Tromboċitopenika jew TTP) li tinkludi deni u tbenġil taħt il-ġilda li jidher bħal tikek ħomor irqaq, flimkien ma' jew mingħajr għeja kbira mhux spjegata, konfużjoni, sfurija tal-ġilda jew ta' l-għajnejn (suffejra) (ara sezzjoni 4 'EFFETTI SEKONDARJI LI JISTA' JKOLLU').
English: Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9can be safely co-administered with clopidogrel.
Maltese: Tagħrif mill-istudju CAPRIE jindika li phenytoin u tolbutamide li jiġu mmetaboliżżati minn CYP2C9 jistgħu jiġu amministrat b'sigurta` flimkien ma' clopidogrel.
English: It also contains hydrogenated castor oil.
Maltese: LISTA TA' SUSTANZI MHUX ATTIVI Fih ukoll castor oil idroġenat.
English: HOW TO STORE CLOPIDOGREL HEXAL
Maltese: Clopidogrel HEXAL;
English: If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel HEXAL in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Maltese: Jekk ħassejt uġigħ qawwi f'sidrek (anġina mhux stabbli jew attakk tal-qalb), jista' jingħatalek Clopidogrel HEXAL flimkien ma' acetylsalicylic acid, sustanza inkorporata f'ħafna mediċini użati biex itaffu l-uġigħ u jnaqqsu d-deni.
English: For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern.
Maltese: Għal qtugħ u feriti żgħar eż. meta taqta' x'imkien, meta tqaxxar, normalment m'hemmx għax tinkwieta.
English: NAME OF THE MEDICINAL PRODUCT Clopidogrel HEXAL 75 mg film-coated tablets Clopidogrel NAME OF THE MARKETING AUTHORISATION HOLDER Acino Pharma GmbH EXPIRY DATE
Maltese: TAD-DETENTUR TA' L-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ Acino Pharma GmbH
English: Further information on Lucentis can be found on the Agency's website:ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This overview was last updated in 08-2018.
Maltese: Din il-ħarsa ġenerali ġiet aġġornata l-aħħar fi: 08-2018.
English: Lucentis received a marketing authorisation valid throughout the EU on 22 January 2007.
Maltese: Lucentis rċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-22 ta' Jannar 2007.
English: The most common side effects with Lucentis (seen in more than 1 in 10 patients) are increased intraocular pressure (pressure within the eye), headache, vitritis (inflammation in the eye), vitreous detachment (separation of the vitreous from the back of the eye), retinal haemorrhage (bleeding at the back of the eye), visual disturbance, eye pain, vitreous floaters (spots in the vision), conjunctival haemorrhage (bleeding at the front of the eye), eye irritation, sensation of a foreign body in the eye, increased lacrimation (tear production), blepharitis (inflammation of the eyelids), dry eye, ocular hyperaemia (red eye), eye pruritis (itching), arthralgia (joint pain) and nasopharyngitis (inflammation of the nose and throat).
Maltese: L-effetti sekondarji l-aktar komuni rrapportati b'Lucentis (li dehru f'aktar minn pazjent wieħed minn għaxra) huma żieda fil-pressjoni intraokulari (pressjoni fl-għajn), uġigħ ta' ras, vitrite (infjammazzjoni fl-għajn), distakk tal-vitreu (separazzjoni tal-vitreu min-naħa ta' wara tal-għajn), emorraġija fir-retina (fsada fin-naħa ta' wara tal-għajn), disturbi viżivi, uġigħ fl-għajn, tikek fil-viżta, emorraġija konġjuntivali (fasda fin-naħa ta' quddiem tal-għajn), irritazzjoni fl-għajn, sensazzjoni ta' traba fl-għajn, żieda fit-tidmiegħ (produzzjoni tad-dmugħ), blefarite (infjammazzjoni tat-tbieqi tal-għajn), għajn xotta, iperimija okulari (ħmura fl-għajn), prurite fl-għajn (ħakk) artralġija (uġigħ fil-ġogi) u nasofarinġite (infjammazzjoni tal-imnieħer u tal-gerżuma).
English: Choroidal neovascularisation
Maltese: Neovaskularizzazzjoni korojdali
English: The recommended dose for Lucentis is 0.5 mg given as a single intravitreal injection.
Maltese: Id-doża rakkomandata għal Lucentis hija ta' 0.5 mg mogħtija bħala injezzjoni intravitreali waħda.
English: The active substance in Lucentis, ranibizumab, is a small piece of a monoclonal antibody.
Maltese: Is-sustanza attiva f'Lucentis, ir-ranibizumab, hija parti żgħira ta' antikorp monoklonali.
English: • macular oedema (swelling of the macula) caused by diabetes;
Maltese: • edema makulari (nefħa tal-makula) ikkawżata mid-dijabete;
English: • other sight problems associated with choroidal neovascularisation;
Maltese: • problemi oħra tal-vista assoċjati ma' neovaskularizzazzjoni korojdali;
English: It is given by intravitreal injection (injection into the vitreous humour, the jelly-like fluid in the eye).
Maltese: Jingħata permezz ta' injezzjoni intravitreali (injezzjoni fl-umor vitreuż, il-fluwidu qisu ġeli flgħajn).
English: Other information about Lucentis
Maltese: Informazzjoni oħra dwar Lucentis
English: After one year, between 94 and 96% of the AMD patients receiving Lucentis every month experienced no significant worsening of their vision, compared with 62% of those receiving sham injections and 64% of those treated with verteporfin PDT.
Maltese: Wara sena, bejn 94 u 96% tal-pazjenti bl-AMD li kienu qed jingħataw Lucentis kull xahar ma esperjenzaw l-ebda tiħżin sinifikanti fil-viżta tagħhom, meta mqabbla ma' 62% ta' dawk li kienu qed jingħataw injezzjonijiet finta u 64% ta' dawk li ġew ikkurati bil-PDT bil-verteporfina.
English: One study compared Lucentis with verteporfin PDT in 277 patients with choroidal neovascularisation associated with pathologic myopia (a severe type of short sightedness).
Maltese: Studju wieħed qabbel Lucentis mal-PDT bilverteporfina f'277 pazjent li kienu jbatu minn neovaskularizzazzoni korojdali assoċjata ma' mijopija patoloġika (tip gravi tal-viżta tal-bogħod).
English: The third study compared Lucentis with verteporfin photodynamic therapy (PDT, another treatment for AMD).
Maltese: It-tielet studju qabbel Lucentis mat-terapija fotodinamika bil-verteporfina (PDT, kura oħra għall-AMD).
English: Rarely, endophthalmitis (an infection inside the eye), blindness, serious damage to the retina and cataract (clouding of the lens) can occur.
Maltese: F'każijiet rari, jistgħu jseħħu każijiet ta' endoftalmite (infezzjoni ġewwa l-għajn), telf tal-viżta, ħsara serja lir-retina u katarretti (tiċpir tallenti).
English: What are the risks associated with Lucentis?
Maltese: X'inhuma r-riskji assoċjati ma' Lucentis?
English: Three main studies of Lucentis involved 1,323 patients with the wet form of AMD.
Maltese: Tliet studji ewlenin ta' Lucentis kienu jinvolvu 1,323 pazjent bit-tip umdu tal-AMD.
English: As for all medicines, data on the use of Lucentis are continuously monitored.
Maltese: Bħal l-mediċini kollha, id-data dwar l-użu ta' Lucentis hija ssorveljata kontinwament.
English: Macular oedema due to occlusion of retinal veins
Maltese: Edema makulari minħabba okklużjoni tal-vini tar-retina
English: Lucentis was more effective than a sham injection: patients receiving Lucentis at the 0.5 mg dose for six months could see around 11 letters more than patients receiving a sham injection in one study and 14 letters more in the other study.
Maltese: Lucentis kien aktar effettiv minn injezzjoni finta: il-pazjenti li kienu qed jingħataw Lucentis f'doża ta' 0.5 mg għal sitt xhur setgħu jaraw madwar 11-il ittra aktar mill-pazjenti li kienu qed jingħataw injezzjoni finta fi studju wieħed u 14-il ittra aktar fl-istudju l-ieħor.
English: For diabetic macular oedema, Lucentis was studied in two main studies involving a total of 454 patients.
Maltese: Għall-edema makulari dijabetika, Lucentis ġie studjat f'żewġ studji ewlenin li kienu jinvolvu total ta' 454 pazjent.
English: In the second study, patients receiving Lucentis on its own or as an add-on to laser photocoagulation could see after one year an average of 5 letters more than patients receiving laser photocoagulation on its own.
Maltese: Fit-tieni studju, il-pazjenti li ngħataw Lucentis waħdu jew bħala żieda għall-fotokoaguluzzjoni bil-laser setgħu, wara sena, jaraw medja ta' 5 ittri aktar mill-pazjenti li saritilhom il-fotokogaluzzjoni bil-laser weħidha.
English: The second study compared Lucentis, given on its own or as an add-on to laser photocoagulation (a treatment for diabetic macular oedema using a laser), with laser photocoagulation on its own.
Maltese: It-tieni studju qabbel Lucentis, mogħti waħdu jew mogħti bħala żieda għall-fotokoagaluzzjoni bil-lejżer (kura bil-lejżer għall-edema makulari dijabetika), mal-fotokoagaluzzjoni bil-lejżer weħidha.
English: • macular oedema caused by occlusion (blockage) of the veins behind the retina.
Maltese: • edema makulari kkawżata minn okklużjoni (imblokk) tal-vini ta' wara r-retina.
English: What measures are being taken to ensure the safe and effective use of Lucentis?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Lucentis?
English: Lucentis is a medicine used to treat adults with certain sight problems caused by damage to the retina (the light-sensing layer at the back of the eye), and more specifically its central region, known as the macula.
Maltese: Lucentis huwa mediċina użata għall-kura ta' adulti b'ċerti problemi tal-vista kkawżati minn ħsara lirretina (is-saff li jsib id-dawl fuq wara tal-għajn), u b'mod aktar speċifiku r-reġjun ċentrali tagħha, magħruf bħala l-makula.
English: All of the patients were over 50 years of age and had not been treated for wet AMD before.
Maltese: Il-pazjenti kollha kellhom aktar minn 50 sena u ma kinux ġew ikkurati għall-AMD umda qabel.
English: The company that makes Lucentis will provide information packs to patients to help them prepare for Lucentis treatment, recognise serious side effects and know when to seek urgent attention from their doctor.
Maltese: Il-kumpanija li tagħmel Lucentis ser tipprovdi pakketti ta' informazzjoni lill-pazjenti biex tgħinhom jippreparaw għal kura b'Lucentis, jirrikonoxxu effetti sekondarji serji u jkunu jafu meta għandhom ifittxu attenzjoni urġenti mit-tabib tagħhom.
English: A second study involved 178 patients with choroidal neovascularisation associated with other conditions, and compared Lucentis with a sham injection.
Maltese: It-tieni studju kien jinvolvi 178 pazjent li kienu jbatu minn neovaskularizzazzjoni korojdali assoċjata ma' kondizzjonijiet oħra, u qabbel Lucentis ma' injezzjoni finta.
English: The conditions Lucentis is used to treat are:
Maltese: Il-kondizzjonijiet li jiġu kkurati b'Lucentis huma:
English: Side effects reported with Lucentis are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati bi Lucentis huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: Two of the studies compared Lucentis with a sham injection ( a procedure similar to a Lucentis injection, in which the syringe is pressed against the surface of the eye but no actual injection is carried out).
Maltese: Tnejn mill-istudji qabblu Lucentis ma' injezzjoni simulata (proċedura simili għal injezzjoni ta' Lucentis, li fiha s-siringa tingħafas mal-wiċċ tal-għajn iżda ma ssir l-ebda injezzjoni attwali).
English: For macular oedema due to retinal vein occlusion, Lucentis was looked at in two main studies involving a total of 789 patients, where Lucentis was compared with a sham injection.
Maltese: Għall-edema makulari minħabba okklużjoni tal-vina tar-retina, saru żewġ studji ewlenin b'Lucentis li kienu jinvolvu total ta' 789 pazjent, fejn Lucentis tqabbel ma' injezzjoni finta.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific target (called an antigen) that is found in certain cells in the body.
Maltese: Antikorp monoklonali huwa antikorp (tip ta' proteina) li tfassal biex jagħraf u jeħel ma' mira speċifika (imsejħa antiġen) li tinstab f'ċerti ċelloli fil-ġisem.
English: The wet form of AMD is caused by choroidal neovascularisation (abnormal growth of blood vessels beneath the retina, which may leak fluid and blood and cause swelling);
Maltese: • il-forma ‘umda' ta' deġenerazzjoni makulari relatata mal-età (AMD); Il-forma umda ta' AMD hija kkawżata minn neovaskularizzazzjoni korojdali (it-tkabbir anormali ta' arterji tad-demm taħt ir retina, li jistgħu jnixxu fluwidu u demm u jikkawżaw nefħa);
English: Ref.: EMEA/634501/2009 EMEA/H/C/1066
Maltese: EMEA/649369/2009 EMEA/H/C/1066
English: It is available as round tablets (white: 0.5 mg; yellow: 1 mg; pink: 2 mg).
Maltese: Huwa disponibbli f'pilloli tondi (bojod: 0.5 mg; sofor: 1 mg; roża:
English: Repaglinide Krka is a ‘generic medicine'.
Maltese: Repaglinide Krka huwa ‘mediċina ġenerika'.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Krka to Krka, d.d., Novo mesto on 4 November 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Repaglinide Krka lil Krka, d.d., Novo mesto fi 4 Novembru 2009.
English: This summary was last updated in 11-2009.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi: 11-2009.
English: Repaglinide Krka is a medicine that contains the active substance repaglinide.
Maltese: Repaglinide Krka huwa mediċina li fiha s-sustanza attiva repaglinide.
English: This means that Repaglinide Krka is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Maltese: Dan ifisser li Repaglinide Krka huwa simili għal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem NovoNorm.
English: Repaglinide Krka is taken before meals, normally up to 15 minutes before each main meal.
Maltese: Repaglinide Krka jittieħed qabel l-ikel, normalment kwarta qabel kull ikla prinċipali.
English: What are the benefit and risk of Repaglinide Krka?
Maltese: X'inhu il-benefiċċju u r-riskju ta' Repaglinide Krka?
English: Because Repaglinide Krka is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, NovoNorm.
Maltese: Billi Repaglinide Krka huwa mediċina ġenerika, l-istudji ġew limitati għal testitjiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċina ta' referenza, NovoNorm.
English: Why has Repaglinide Krka been approved?
Maltese: Għaliex ġie approvat Repaglinide Krka?
English: Repaglinide Krka helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Maltese: Repaglinide Krka jgħin lill-frixa tipproduċi iktar insulina f'ħin l-ikel u jintuża biex jikkontrolla dijabete tat-tip 2.
English: What is Repaglinide Krka?
Maltese: Kif jintuża Repaglinide Krka?
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Repaglinide Krka has been shown to have comparable quality and to be bioequivalent to NovoNorm.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Repaglinide Krka wera li għandu kwalità komparabbli ma' u huwa bijoekwivalenti għal NovoNorm.
English: Other information about Repaglinide Krka:
Maltese: Aktar tagħrif dwar Repaglinide Krka:
English: Because Repaglinide Krka is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Maltese: Minħabba li Repaglinide Krka huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċju u r-riskju tiegħu huma meqjusa analogi għal dawk tal-mediċina ta' referenza.
English: Repaglinide Krka is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Maltese: Repaglinide Krka jintuża fit-trattament ta' pazjenti adulti li jbatu mid-dijabete tat-tip 2 (dijabete mhux dipendenti mill-insulina).
English: Repaglinide Krka is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Maltese: Repaglinide Krka mhux rakkomandat sabiex jintuża f'pazjenti ta' inqas minn 18-il sena minħabba nuqqas ta' tagħrif dwar is-sigurtà u l-effikaċja f'dan il-grupp.
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size EU/1/15/1021/001 Pregabalin Zentiva 25 mg Capsule, hard
Maltese: Il-pakkett li jmiss mal-prodott
English: EU/1/98/064/001 Pylobactell
Maltese: EU/1/98/064/001 Pylobactell 100 mg pillola li tinħall tittieħed mill-ħalq Qartas
English: Pylobactell tablet - 6 glass tubes with caps and bar code labels - 3 additional bar code labels - 30 ml mixing and administration vial.
Maltese: - Sitt tubi tal-ħġieġ, bit-tappijiet u t tikketti tal-bar kowd. - tliet tikketti oħra bil-bar kowd. - Kunjett tal-ħġieġ ta' 30 ml bit-tapp, biex tħallat u minn fejn tagħti l-prodott.
English: Packaging Content
Maltese: Daqs tal-pakkett
English: Sachet one tablet in a multicomponent test kit
Maltese: Pillola waħda f'kitt tat-test li fih ħafna komponenti
English: 100 mg Soluble tablet oral use
Maltese: Qawwa Għamla farmaċewtika
English: EU Number Invented name Strength Pharmaceutical form Route of administration
Maltese: Numru ta' l-EU Isem inventat
English: One test kit contains: - 1 sealed sachet containing 1
Maltese: Mnejn jingħata Il-pakkett Kontenut
English: Rheumocam (meloxicam)
Maltese: Rheumocam (melossikam)
English: Rheumocam received a marketing authorisation valid throughout the EU on 10 January 2008.
Maltese: Rheumocam ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fl-10 ta' Jannar 2008.
English: Other information about Rheumocam
Maltese: Informazzjoni oħra dwar Rheumocam
English: Rheumocam contains the active substance meloxicam and is a generic medicine.
Maltese: Rheumocam fih is-sustanza attiva melossikam u huwa mediċina ġenerika.
English: The withdrawal period for meat is five days for the 20 mg/ml solution for injection and three days for the granules in sachet and 15 mg/ml oral suspension.
Maltese: Għal-laħam il-perjodu ta' tiżmim huwa ħamest ijiem għas-soluzzjoni għall-injezzjoni ta' 20 mg/ml u tlett ijiem għall-granuli fil-qratas u għas-soluzzjoni orali ta' 15 mg/ml.
English: Rheumocam is available as granules, an oral (taken by mouth) suspension, chewable tablets and a solution for injection.
Maltese: Rheumocam huwa disponibbli bħala granuli, bħala sospensjoni orali (meħud oralment), pilloli talmagħad u soluzzjoni għall-injezzjoni.
English: Rheumocam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Maltese: Rheumocam fih il-melossikam, li tagħmel parti minn klassi ta' mediċini msejħa mediċini antiinfjammatorji nonsterojdali (NSAIDs).
English: In cattle, Rheumocam is used together with appropriate antibiotic therapy, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways).
Maltese: Fil-frat, Rheumocam jintuża flimkien ma' terapija antibijotika adatta, biex inaqqas is-sintomi kliniċi talinfezzjoni respiratorja akuta (infjammazzjoni fil-pulmun u fil-passaġġi tal-arja).
English: In pigs, Rheumocam is used to reduce lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move), for the relief of post-operative pain after minor soft tissue surgery such as castration, and for supportive therapy together with appropriate antibiotic therapy in the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Maltese: Fil-ħnieżer, Rheumocam, jintuża biex titnaqqas iz-zappip u l-infjammazzjoni f'diżordnijiet lokomotriċi mhux infettivi (mard li jaffettwa l-abbiltà li wieħed jiċċaqlaq), għat-taffija tal-uġigħ li jinħass wara operazzjonijiet assoċjati ma' interventi kirurġiċi fuq it-tessut artab minuri bħall-kastrazzjoni, u bħala terapija supplimentari flimkien ma' terapija bl-antibijotiċi adatti fil-kura ta' mard li jiżviluppa wara ttifrigħ (twelid) bħas-settiċemija pwerperali u t-tossjemija (sindromu tal-mastite-metrite-agalassija).
English: Since Rheumocam is a generic medicine, studies have been conducted to determine that it is bioequivalent to the reference medicine, Metacam.
Maltese: Billi Rheumocam huwa mediċina ġenerika, l-istudji ġew limitati għal testijiet biex jistabbilixxu lbijoekwivalenza tiegħu mal-mediċina ta' referenza, Metacam.
English: Why is Rheumocam authorised in the EU?
Maltese: Għaliex Rheumocam huwa awtorizzat fl-UE?
English: Meloxicam acts by blocking an enzyme called cyclo-oxygenase which is involved in the production of prostaglandins.
Maltese: Il-melossikam taġixxi billi jimblokka enzima msejħa ċiklossiġenażi li hija involuta fil-produzzjoni tal-prostaglandini.
English: How has Rheumocam been studied?
Maltese: Kif ġie studjat Rheumocam?
English: This means that Rheumocam contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Metacam.
Maltese: Dan ifisser li Rheumocam fih l-istess sustanza attiva u jaħdem bl-istess mod ta' “mediċina ta' referenza” diġà awtorizzata fl-Unjoni Europea (UE) msejħa Metacam.
English: As prostaglandins are substances that trigger inflammation, pain, exudation (fluid that leaks out of blood vessels during an inflammation) and fever, meloxicam reduces these signs of disease.
Maltese: Peress li l-prostaglandini huma sustanzi li jiskattaw l-infjamazzjoni, l-uġigħ, it-tnixxija (fluwidu li joħroġ mill-vażi waqt infjamazzjoni) u d-deni, meloxicam tnaqqas dawn is-sinjali tal-marda.
English: The precautions are the same as for the reference medicine since Rheumocam is a generic medicine.
Maltese: Il-prekawzjonijiet huma bħal dawk tal-mediċina ta' referenza minħabba li Rheumocam huwa mediċina ġenerika.
English: In cats, Rheumocam is used to reduce post-operative pain and inflammation after ovariohysterectomy (spaying operation), orthopaedic and minor soft tissue surgery.
Maltese: Fil-qtates, Rheumocam jintuża biex inaqqsilhom l-uġigħ u l-infjammazzjoni wara li tkun saritilhom ovarjoisterektomija (operazzjoni li tneħħi l-ovarji u l-utru), intervent kirurġiku ortopediku u intervent kirurġiku fuq it-tessut artab.
English: In dogs, Rheumocam is used to reduce post-operative pain and inflammation following orthopaedic (e.g. fracture operation) and soft tissue surgery.
Maltese: Fil-klieb, Rheumocam jintuża biex inaqqsilhom l-uġigħ u l-infjammazzjoni wara li tkun saritilhom operazzjoni ortopedika b'intervent kirurġiku (e.g. operazzjoni fuq ksur) u intervent kirurġiku fuq ittessut artab.
English: It can be used as supportive therapy in the treatment of acute mastitis (inflammation of the udder), in combination with antibiotics.
Maltese: Jista' jintuża wkoll bħala terapija ta' appoġġ fil-kura ta' mastite akuta (infjammazzjoni tal-glandola mammarja), flimkien mal-antibijotiċi.
English: Because Rheumocam is a generic and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Rheumocam huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.